GUIDED THERAPEUTICS INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
GTHPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Exhibit Description |
| 3.1 | Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016) |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012) |
| 3.3 | Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018) |
| 3.4 | Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021) |
| 3.6 | Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021) |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021) |
| 3.8 | Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022) |
| 3.9 | Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022) |
| 10.1* | $100,000 Promissory Note Dated June 28, 2024 and Related Common Stock Purchase Warrant |
| 10.2* | Exchange Agreement dated April 15, 2024 |
| 10.3* | Securities Purchase Agreement with 1800 Diagonal Lending |
| 10.4* | $100,050 Promissory Note Dated June 11, 2024 with 1800 Diagonal Lending |
| 10.5* | $50,000 Promissory Note Dated July 23, 2024 and related Common Stock Purchase Warrant Dated August 1, 2024 |
| 10.6* | Form of Promissory Notes Issued to Directors and Form of Related Common Stock Purchase Warrants |
| 10.7* | Securities Purchase Agreement with 1800 Diagonal Lending, dated July 22, 2024 |
| 10.8* | $62,100 Promissory Note Dated July 22, 2024 with 1800 Diagonal Lending |
| 31* | Rule 13a-14(a)/15d-14(a) Certification |
| 32* | Section 1350 Certification |
| 101.1* | Interactive data files for Guided Therapeutics, Inc. 's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL: (i) the Unaudited Condensed Consolidated Balance Sheets; (ii) the Unaudited Condensed Consolidated Statements of Income; (iii) the Unaudited Condensed Consolidated Statements in Stockholders' Deficit; (iv) the Unaudited Condensed Consolidated Statements of Cash Flows; and (v) the Notes to the Unaudited Condensed Consolidated Financial Statements. |
| 104 | The cover page from Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (formatted in Inline XBRL and included in Exhibit 101) |
*Filed herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GUIDED THERAPEUTICS, INC. | |
| By: | /s/ Mark Faupel |
| Mark Faupel | |
| President, Chief Executive Officer, Chief OperatingOfficer and Acting Chief Financial Officer |
Date: August 14, 2024
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.